Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinacalcet daily versus every-other-day dosing for secondary hyperparathyroidism in hemodialysis patients
IRCT20150706023084N28Phase 3Completed
- Sponsor
- Islamic Azad University
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cinacalcet in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Islamic Azad University. Primary endpoint: Parathyroid hormone. Started Sep 2025; status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on IRCT20150706023084N28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150706023084N28.